The study, conducted by a team of Egyptian researchers from Cairo University, enrolled twenty-two patients with confirmed oral pemphigus vulgaris and randomly assigned them into two equal groups. Both groups continued their standard systemic therapy, typically the immunosuppressive medication backbone that pemphigus care depends on. The experimental group, however, also received low-level laser therapy, or LLLT, applied three times weekly for four weeks directly to the oral lesions. The control group received systemic treatment alone. The design was deliberately simple and clinically relevant: the question was not whether lasers could replace drugs, but whether they could meaningfully augment them.

Low-level laser therapy, sometimes called photobiomodulation, is fundamentally different from the surgical lasers most people imagine. Instead of cutting or vaporizing tissue, these low-energy diode devices deliver light at intensities low enough to avoid heating or damaging cells. The photons are absorbed by chromophores inside mitochondria, particularly components of the respiratory chain, which is thought to boost cellular energy production, modulate inflammatory signaling and stimulate the proliferation of fibroblasts and endothelial cells. Decades of research have explored this mechanism in wound healing, ulcer care and pain management, and the pemphigus field had already seen intriguing case reports and small pilot studies hinting at benefit. What was missing was controlled trial data in oral pemphigus specifically, which is precisely the gap this study set out to fill.

The researchers assessed outcomes using a battery of complementary measures. Ulcer size was tracked by measuring changes in lesion length, and pain was quantified with the visual analog scale, the standard patient-reported tool in which zero represents no pain and ten the worst imaginable discomfort. Disease severity in the mouth was scored with the Pemphigus Oral Lesions Intensity Score, known as POLIS, a validated instrument designed specifically for grading the intensity of oral pemphigus lesions. To probe the biology beneath the clinical surface, the team also measured tissue levels of tumor necrosis factor alpha, a pro-inflammatory cytokine central to autoimmune inflammation, using enzyme-linked immunosorbent assay. Every measurement was taken before treatment began and again after the four-week course, allowing within-patient and between-group comparisons.

The most striking results concerned ulcers and pain. Patients who received the combined laser-plus-medication regimen showed significantly greater reductions in ulcer length and significantly lower visual analog scale scores than those on medication alone, with both differences reaching a p-value below 0.001. In practical terms, the laser-treated group saw their wounds shrink faster and their day-to-day pain drop more steeply over the four weeks. For a disease in which oral pain is often the single most disabling complaint, that finding carries real weight. Faster mucosal healing also matters beyond comfort, because open oral ulcers can impair nutrition and serve as gateways for secondary infection in patients whose immune systems are already dampened by systemic therapy.

The picture was more nuanced for overall disease severity. Both groups experienced significant decreases in their POLIS scores after four weeks, with p-values of 0.006 in the laser group and 0.003 in the control group, reflecting the fact that standard systemic therapy does work on its own. However, the difference in POLIS improvement between the two groups did not reach statistical significance, registering at p equal to 0.101. This suggests that the laser’s clearest contribution was to the local problems, ulcer size and pain, rather than to the global intensity score of oral lesions over this relatively short treatment window. It is a distinction that matters for clinicians deciding what the laser is actually adding to the therapeutic equation.

The inflammatory biomarker told a similar story of direction without decisive divergence. Tumor necrosis factor alpha levels decreased within each group over the treatment period, consistent with the anti-inflammatory effect of systemic pemphigus therapy and possibly with photobiomodulation’s immunomodulatory reputation. Yet when the researchers compared the percent change between the laser group and the control group, the difference was not statistically significant. The study was small, with only eleven patients per arm, and modest sample sizes limit the power to detect subtle shifts in molecular markers. The cytokine data therefore remain hypothesis-generating rather than conclusive, and larger trials with longer follow-up would be needed to establish whether laser therapy measurably dampens the inflammatory cascade in pemphigus tissue.

Satisfaction and physician assessment added an interesting human dimension. Patient satisfaction scores were similar between the two groups, but the physician global assessment scores differed significantly between groups, and the authors noted that patients in the laser group were more satisfied. The divergence between patient and physician ratings is a reminder that healing trajectories and subjective experience do not always move in lockstep, and that instruments capturing different perspectives can disagree even within the same trial. The authors also emphasized tolerability, reporting that the therapy was safe and well accepted, which is a crucial consideration for patients already managing the considerable side-effect load of long-term corticosteroids and immunosuppressants.

The trial’s limitations deserve honest acknowledgment. Twenty-two patients is a small cohort, and the four-week follow-up captures early response rather than long-term control of a disease that often requires months to years of management. The study also did not report blinding details in a way that would fully eliminate performance bias, which is inherently difficult when one group can feel the laser device at work. Still, the randomized design, the use of validated outcome instruments such as POLIS and the visual analog scale, and the objective measurement of ulcer dimensions and cytokine levels give the findings a credibility that earlier case reports could not achieve. The results align with a growing literature on photobiomodulation in oral inflammatory disease, including randomized work in recurrent aphthous stomatitis and pilot studies of laser therapy in pemphigus lesions.

What does this mean for patients and clinicians today? The evidence supports low-level diode laser therapy as a safe, well-tolerated adjunct that can accelerate ulcer healing and reduce pain in oral pemphigus vulgaris when layered on top of standard systemic treatment, not as a replacement for it. For a condition in which the oral cavity is frequently the first and most stubborn site of involvement, a noninvasive, drug-free tool that targets exactly that site is an appealing addition to the therapeutic arsenal. Larger, blinded, longer-duration trials will be needed before laser sessions become routine in pemphigus clinics worldwide, but this trial moves photobiomodulation from anecdote toward evidence, and offers a glimpse of a future in which light itself becomes part of the prescription for one of medicine’s most painful autoimmune diseases.

Subject of Research: Low-level laser therapy as an adjunctive treatment for oral pemphigus vulgaris

Article Title: Efficacy and tolerability of low-level diode laser therapy as an adjunctive in the treatment of oral pemphigus vulgaris, a randomized controlled trial

Article References: Efficacy and tolerability of low-level diode laser therapy as an adjunctive in the treatment of oral pemphigus vulgaris, a randomized controlled trial. (n.d.). https://doi.org/10.1007/s00403-026-04875-2

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04875-2

Keywords: pemphigus vulgaris, low-level laser therapy, photobiomodulation, diode laser, oral ulcers, wound healing, pain management, TNF alpha, autoimmune blistering disease, randomized controlled trial, POLIS score, visual analog scale